Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo to Acquire Plexxikon
March 7, 2011
- AZ Ordered to Pay Damages, Gov't Responsibility Denied: Iressa Trial
March 7, 2011
- Prazaxa Expected to Be Effective, Convenient: Prof. Uchiyama
March 7, 2011
- Develop Biomarkers with Therapeutic Agents: Dr Suzuki of Roche Pharma Japan
March 7, 2011
- Azilsartan Approved by FDA: Takeda
March 7, 2011
- BMKK Aims at Top-20 Position in Japan by 2015
March 7, 2011
- Novartis to Expand SOV for Equa through Comarketing with Sanofi-aventis
March 7, 2011
- JPO's Decision on Actos Patent Infringement Case Expected Soon
March 7, 2011
- FUJIFILM to Acquire 2 Contract Biopharmaceuticals Manufacturers from US Merck
March 7, 2011
- Aricept's Patent Period Extension Upheld by IP High Court
March 7, 2011
- Top 4 Products Neck and Neck in Global Market for Antibody Drugs
March 7, 2011
- Prof. Yamanaka, Dr Kondo of PMDA Discuss Toxicity Assessment for iPS Cells-Derived Products
March 7, 2011
- Kyorin Licenses Aclidinium from Almirall
March 7, 2011
- Merck Serono Withdraws MAA for Cladribine
March 7, 2011
- Yakult Ties Up with Proacta to Commercialize Anticancer Drugs
March 7, 2011
- Gov't Bought Vaccines for New Type Flu at \905.50 per Dose
March 7, 2011
- Sanofi-aventis to Transfer Long-Listed Products to Nichi-Iko
March 7, 2011
- Takeda to Develop New Drugs with Unmet Medical Needs at New Research Center
March 7, 2011
- Mochida Recalls Its Generic Heparin Ca
March 7, 2011
- Shionogi to Create GDO to Accelerate Global Development
March 7, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…